| Cell line name |
NCI-H2228-ARY |
|---|
| Synonyms |
H2228-ARY |
|---|
| Accession |
CVCL_E6DB |
|---|
| Resource Identification Initiative |
To cite this cell line use: NCI-H2228-ARY (RRID:CVCL_E6DB) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_62268; Alectinib (CH5424802; RO5424802; AF-802).
Derived from site: In situ; Lung; UBERON=UBERON_0002048. |
|---|
| Sequence variations |
- Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK; Note=E6A20 v3 fusion (from parent cell line).
- Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:9655; PTPN3; Name(s)=ALK-PTPN3 (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Lung adenocarcinoma (NCIt: C3512) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_1543 (NCI-H2228) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
Age unspecified |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=31900393; DOI=10.1038/s41467-019-13771-5; PMCID=PMC6941996
Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo ...Show all 17 authors... , Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai; Show fewer authors
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation.
Nat. Commun. 11:74.1-74.16(2020) |
|---|
| Entry history |
|---|
| Entry creation | 10-Apr-2025 |
|---|
| Last entry update | 10-Apr-2025 |
|---|
| Version number | 1 |
|---|
